Base de dados : LILACS
Pesquisa : D10.532.515 [Categoria DeCS]
Referências encontradas : 252 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 26 ir para página                         

  1 / 252 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-832378
Autor: Biano, Henrique Tria; Araújo, Daniel Branco de.
Título: Exposição aos níveis de colesterol ao longo da vida e doença coronariana / Lifetime exposure to cholesterol evels and coronarysrtery disease disease
Fonte: Rev. Soc. Cardiol. Estado de Säo Paulo;26(3):158-161, jul.-set. 2016. tab.
Idioma: pt.
Resumo: A doença aterosclerótica compreende amplo espectro de entidades clínicas com envolvimento genético e ambiental. A exposição ao longo da vida a níveis elevados de colesterol e de sua fração LDL determinam um limiar a partir do qual a doença aterosclerótica se desenvolve. Assim, nas formas genéticas de dislipidemias, como a hipercolesterolemia familiar, a idade do aparecimento da doença aterosclerótica vai depender da carga cumulativa de exposição aos níveis de LDL-colesterol, sendo tanto mais precoce quanto maiores os níveis de LDL-colesterol e a presença de fatores de risco adicionais, e mais tardia na ausência destes, e no sexo feminino. A prevenção ao longo da vida parece ser extremamente efetiva, e a avaliação individual com a implementação de medidas preventivas precoces e terapêuticas deve ser estimulada. Assim, parece lógico que reduções de colesterol, por mudanças no estilo de vida ou pelo uso de fármacos na adolescência e ao longo da vida apresentem inestimável benefício para a redução dos desfechos cardiovasculares na vida adulta

The atherosclerotic process comprises a broad spectrum of clinical entities, with genetic and environmental involvement. Lifetime exposure to high levels of cholesterol and LDL-cholesterol determine a trigger that can lead to the development of atherosclerotic disease. Therefore, in genetic forms of dyslipidemia, such as familial hypercholesterolemia, the age of onset of atherosclerotic disease will depend on the cumulative burden of exposure to LDL-cholesterol levels, being earlier with higher levels of LDL-cholesterol, the presence of other risk factors and later, in the absence of risk factors, and in females. Prevention throughout life appears to be extremely effective, and individual assessment, with the implementation of early preventive measures, should be encouraged. Thus, it seems logical that cholesterol reductions, changes in lifestyle, or the use of specific medications in adolescence and throughout life present inestimable benefit in reducing cardiovascular outcomes in adulthood
Descritores: Doença da Artéria Coronariana/fisiopatologia
Colesterol/sangue
Fatores de Risco
Diagnóstico Diferencial
-Qualidade de Vida
Doenças Cardiovasculares/prevenção & controle
Fatores Sexuais
Doença Crônica
Fatores Etários
Aterosclerose/complicações
Aterosclerose/diagnóstico
Hipercolesterolemia/complicações
Hipercolesterolemia/terapia
Estilo de Vida
Lipoproteínas LDL/análise
LDL-Colesterol/análise
LDL-Colesterol/sangue
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: BR44.1 - Serviço de Biblioteca, Documentação Científica e Didática Prof. Dr. Luiz Venere Décourt


  2 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-832393
Autor: Rocha, Viviane Zorzanelli; Miname, Marcio Hiroshi.
Título: Critérios diagnósticos e estratificação de risco na hipercolesterolemia familiar / Criteria diagnosis and risk stratification of familial hypercholesterolemia
Fonte: Rev. Soc. Cardiol. Estado de Säo Paulo;26(3):166-173, jul.-set. 2016. tab.
Idioma: pt.
Resumo: A hipercolesterolemia familiar (HF) é uma doença genética relativamente comum caracterizada por níveis elevados de LDL-colesterol (LDL-C) e, por conseguinte, associada a risco de desenvolvimento prematuro de doença cardiovascular aterosclerótica. O tratamento hipolipemiante reduz significativamente o risco cardiovascular desses pacientes, tornando fundamental a identificação precoce desses indivíduos, seguida de tratamento adequado assim que possível. Para tanto, existem escores diagnósticos de HF, como o escore holandês Dutch Lipid Clinic Network, que avalia níveis de LDL-C, antecedente familiar e/ou pessoal de evento cardiovascular isquêmico e a presença de sinais físicos, como xantomas. Uma vez feito o diagnóstico de HF, torna-se muito importante a estratificação de risco desses pacientes. A identificação de fatores de risco associados (como tabagismo,diabetes mellitus, hipertensão arterial, aumento de Lp(a), entre outros) aliada ao uso de métodos para detecção de doença aterosclerótica subclínica em indivíduos com HF pode auxiliar na identificação daqueles que têm maior risco cardiovascular e são candidatos a estratégias mais agressivas de redução de LDL-C. Nesse artigo, revisamos os principais critérios diagnósticos de HF e a estratificação de risco desses pacientes

Familial hypercholesterolemia (FH) is a relatively common genetic disease that is characterized by elevated LDL-cholesterol (LDL-C) levels. As a consequence, it is associated with the risk of premature development of atherosclerotic cardiovascular disease.Lipid-lowering therapies significantly reduces the cardiovascular risk in these patients, making early identification of these individuals essential, followed by adequate treatment as soon as possible. There are diagnostic scores of FH for this purpose, such as the Dutch Lipid Clinic Network score, which evaluates LDL-C levels, family history and/or personal history of ischemic cardiovascular event and the presence of physical signs, such as xanthomas. Once FH has been diagnosed, it is very important to stratify the risk in these patients. The identification of associated risk factors (such as smoking, diabetes mellitus, high blood pressure, elevated Lp(a), among others), together with the use of methods to detect subclinical atherosclerotic disease in individuals with FH, can assist in the identification of those with a higher cardiovascular risk, and who are therefore candidates for more aggressive strategies to reduce LDL-C. This article gives a review of the main diagnostic criteria of FH, and the risk stratification in these patients
Descritores: Doenças Cardiovasculares/fisiopatologia
Fatores de Risco
Técnicas e Procedimentos Diagnósticos
Hiperlipoproteinemia Tipo II/complicações
Hiperlipoproteinemia Tipo II/diagnóstico
LDL-Colesterol/genética
LDL-Colesterol/sangue
-Doença da Artéria Coronariana/complicações
Xantomatose/complicações
Xantomatose/diagnóstico
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Aterosclerose/fisiopatologia
Lipoproteínas LDL
Limites: Humanos
Masculino
Feminino
Criança
Adolescente
Tipo de Publ: Revisão
Responsável: BR44.1 - Serviço de Biblioteca, Documentação Científica e Didática Prof. Dr. Luiz Venere Décourt


  3 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-761236
Autor: Fonseca, Francisco Helfenstein; Izar, Maria Cristina de Oliveira.
Título: Anticorpos monoclonais anti PCSK9 / Anti-PCSK9 monoclonal antibodies
Fonte: Rev. Soc. Cardiol. Estado de Säo Paulo;24(4):18-22, out.-dez. 2014.
Idioma: pt.
Resumo: Inibição da PCSK9 constitui um dos mais promissores avanços para o tratamento da hipercolesterolemia nos últimos anos. Esta pró-proteína convertase ao interagir com a LDL e seu receptor hepático determina a degradação do receptor. Por meio de anticorpos monoclonais, esta ação é inibida na corrente circulatória e, desta forma, o receptor após captar a LDL pode ser reciclado muitas vezes, permitindo eficiente redução do LDL-colesterol. Estes fármacos se mostraram surpreendentemente bem tolerados, com perfil de segurança similar ao placebo e produziram reduções no LDL-C ao redorde 60%, independentemente de terapia prévia com outros hipolipemiantes como estatinas ou ezetimiba. Além disso,reduzem também a lipoproteína Lp (a), uma ação que não se observa com as estatinas. Estudos prospectivos destinado sao exame do impacto em desfechos cardiovasculares estão atualmente em curso e poderão ampliar as indicações hoje previstas, como seu uso para hipercolesterolemias primárias graves ou intolerância a estatinas.

Inhibition of PCSK9 constitutes one of the most promising advances for the treatment of hypercholesterolemia in thelast years. This proprotein convertase interacts with LDLand its receptor determining degradation of the receptor.Through the use of monoclonal antibodies, this effectis inhibited in the bloodstream, and thus, after the LDL capture, the receptor can be recycled many times, promotingan effective LDL-C decrease. Surprisingly, these drugsshowed safety profile similar to placebo and were very well tolerated, achieving LDL-C lowering around 60%, beyond previous therapies with statins or ezetimibe. In addition, these drugs also decrease lipoprotein Lp (a), an effect not observed with statins. Prospective studies aimedto evaluate the impact of treatment on cardiovascular eventsare currently ongoing and they may increase the possible indications recognized today, such as severe primary hypercholesterolemias or statin intolerance.
Descritores: Doença das Coronárias/complicações
Doença das Coronárias/metabolismo
Doença das Coronárias/tratamento farmacológico
Hiperlipoproteinemia Tipo II/tratamento farmacológico
-Anticorpos Monoclonais
Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia
Lipoproteínas LDL/sangue
Limites: Humanos
Responsável: BR44.1 - Serviço de Biblioteca, Documentação Científica e Didática Prof. Dr. Luiz Venere Décourt


  4 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-974943
Autor: Freitas, Maria Camila Pruper de; Fernandez, Diana Gabriela Estevez; Cohen, Danielle; Figueiredo-Neto, Antônio Martins; Maranhão, Raul Cavalcante; Damasceno, Nágila Raquel Teixeira.
Título: Oxidized and electronegative low-density lipoprotein as potential biomarkers of cardiovascular risk in obese adolescents
Fonte: Clinics;73:e189, 2018. tab, graf.
Idioma: en.
Projeto: FAPESP.
Resumo: OBJECTIVES: To evaluate biomarkers associated with early cardiometabolic risk in obese adolescents. METHODS: This cross-sectional study included 137 adolescents of both sexes aged 10 to 19 years divided into a normal weight group (NW) (n=69) and an obese group (OB) (n=68). RESULTS: As expected, obesity showed positive associations with homeostatic model assessment for insulin resistance (HOMA-IR), triacylglycerol, insulin, plasma levels of non-esterified fatty acids, and cholesterol ester transfer protein activity and negative associations with plasma antioxidant levels. Plasma oxidized low-density lipoprotein (oxLDL) and electronegative low-density lipoprotein [LDL(-)] levels were significantly higher in the OB group. Higher tertiles of oxLDL were associated with increased values of body mass index; waist circumference; fatty mass percentage (%FM); and the atherogenic lipids non-high-density-lipoprotein cholesterol (non-HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B and triacylglycerol. Higher tertiles of LDL(-) were robustly associated with body mass index and waist circumference. Logistic regression models (odds ratios) confirmed that increased values of lipids and apolipoprotein B were associated with increased risk of oxLDL. For LDL(-), these associations were not significant, suggesting that another mechanism is involved in generating this particle in obese adolescents. CONCLUSIONS: Obese adolescents showed increased plasma LDL(-) and oxLDL, and obese girls had more LDL(-) than obese boys. Therefore, oxLDL is strongly and independently associated with classical cardiovascular risk factors, while increased levels of LDL(-) were influenced by body mass index, waist circumference and demographic parameters in obese adolescents.
Descritores: Doenças Cardiovasculares/sangue
Lipoproteínas LDL/sangue
Obesidade/sangue
-Biomarcadores/sangue
Doenças Cardiovasculares/etiologia
Índice de Massa Corporal
Estudos de Casos e Controles
Estudos Transversais
Fatores de Risco
Circunferência da Cintura
Obesidade/complicações
Limites: Humanos
Masculino
Feminino
Criança
Adolescente
Adulto Jovem
Responsável: BR1.1 - BIREME


  5 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Maranhäo, Raul C
Baracat, Edmund C
Texto completo
Id: biblio-1011914
Autor: Bedin, Alessandra; Maranhão, Raul C; Tavares, Elaine R; Carvalho, Priscila O; Baracat, Edmund C; Podgaec, Sérgio.
Título: Nanotechnology for the treatment of deep endometriosis: uptake of lipid core nanoparticles by LDL receptors in endometriotic foci
Fonte: Clinics;74:e989, 2019. tab, graf.
Idioma: en.
Resumo: OBJECTIVE: Rapidly dividing cells in multiple types of cancer and inflammatory diseases undergo high low density lipoprotein (LDL) uptake for membrane synthesis, and coupling an LDL-like nanoemulsion, containing lipid nanoparticles (LDE) to a chemotherapeutic agent efficiently targets these cells without significant systemic effects. This was a prospective exploratory study that evaluated the uptake of a radioactively labeled LDE emulsion by receptors of endometriotic foci and the capacity of the LDE for cellular internalization. METHODS: The lipid profile of each patient was determined before surgery, and labeled LDE were injected into fourteen patients with intestinal or nonintestinal endometriosis. The radioactivity of each tissue sample (intestinal endometriosis, nonintestinal endometriosis, healthy peritoneum, or topical endometrium) was measured. RESULTS: The group with intestinal endometriosis presented higher levels of plasma LDL but lower LDE uptake by foci than the nonintestinal group, suggesting less cell division and more fibrosis. The uptake of LDE was highest in the topical endometrium, followed by the healthy peritoneum, and lowest in the endometriotic lesion. Since the endometriotic foci showed significant LDE uptake, there was likely increased consumption of LDL by these cells, similar to cells in cancers and inflammatory diseases. Plasma cholesterol levels had no influence on LDE uptake, which showed that the direct delivery of the nanoemulsion to target tissues was independent of serum lipoproteins. There were no significant differences in the parameters (p>0.01) because of the small sample size, but the findings were similar to those of previous studies. CONCLUSION: Nanotechnology is a promising therapeutic option for surgery and hormonal blockage for deep endometriosis, with a lower complication rate and no systemic side effects.
Descritores: Receptores de LDL/uso terapêutico
Nanotecnologia/métodos
Endometriose/terapia
Nanopartículas/uso terapêutico
-Estudos Prospectivos
Emulsões
Endometriose/fisiopatologia
Intestinos
Lipídeos
Lipoproteínas LDL
Limites: Humanos
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Adulto Jovem
Responsável: BR1.1 - BIREME


  6 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1088634
Autor: Tecer, Duygu; Sunar, Ismihan; Ozdemirel, Ali Erhan; Tural, Rabia; Kucuksahin, Orhan; Dincel, Aylin Sepici; Ataman, Sebnem.
Título: Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?
Fonte: Adv Rheumatol;59:49, 2019. tab.
Idioma: en.
Resumo: Abstract Background: To investigate the link between carbamylated low-density lipoprotein (ca-LDL), atherogenic index of plasma (AIP), atherogenic coefficient (AC), Castelli's risk indices I and II (CRI I and II) and subclinic atherosclerosis in psoriatic arthritis (PsA). Methods: Thirty-ninepatients and 19 age, sex, body mass index matched healthy controls were included. Insulin resistance (IR) was assessed with homeostasis of model assessment-IR (HOMA-IR). Carotid intima-media thickness (CIMT) was measured at both common carotid arteries and mean CIMT was calculated. Results: The mean age was 49.50 ± 11.86 years and 64.1% were females in PsA group. In the PsA group, CIMT and HOMA-IR were significantly higher (p = 0.003, p = 0.043, respectively). AIP, AC, TG/HDL, CRI-1, CRI-2 and ca- LDL levels were similar between groups. In PsA group, CIMT was positively correlated with HOMA-IR, TG/HDL and AIP. Although ca-LDL was positively correlated with serum amyloid A (r = 0.744, p <0.001), no correlation was detected between ca-LDL and CIMT (r =0.215, p = 0.195). PsA patients with IR tended to have higher ca-LDL levels than patients without IR, but this difference lacked statistical significance (33.65 ± 26.94, 28.63 ± 28.06, respectively, p = 0.237). Conclusions: A significant increase in CIMT was seen in PsA patients without clinically evident cardiovascular disease or any traditional atherosclerosis risk factors. CIMT was correlated with HOMA-IR, TG/HDL and AIP.
Descritores: Artrite Psoriásica/fisiopatologia
Aterosclerose/diagnóstico
-Dieta Aterogênica
Espessura Intima-Media Carotídea
Lipoproteínas LDL/análise
Limites: Humanos
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  7 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Texto completo
Id: biblio-1222385
Autor: Torres Valdez, Maritza; Muñoz Avila, Lorena Alexandra; Ortega Espinoza, Carlos Enrique; Mora Bravo, Franklin Geovany; Barzallo Zeas, Diego Fernando.
Título: Reducción de eventos cardiovasculares de Lomitapida versus Estatinas en pacientes con diagnóstico de hipercolesterolemia fa-miliar. Protocolo de revisión sistemática / Reduction of cardiovascular events of Lomitapida versus Statins in patients with a diagnosis of familial hypercholesterolemia: A systematic review protocol
Fonte: Rev. ecuat. pediatr;22(1):1-10, Abril 30, 2021.
Idioma: en.
Resumo: Introducción: La hipercolesterolemia familiar (HF) un trastorno genético autosómico domi-nante que produce un desarrollo prematuro de enfermedades cardiovasculares. Las estati-nas han sido el medicamento de elección en estos pacientes, sin embargo, un buen por-centaje de pacientes no pueden alcanzar sus objetivos terapéuticas con las dosis máximas por lo que la Lomitapida se podría establecer como una nueva alternativa de tratamiento. Objetivo: El objetivo de esta revisión sistemática es determinar si la Lomitapida reduce los eventos cardiovasculares en pacientes con diagnóstico de Hipercolesterolemia familiar comparado con estatinas. Métodos: Se incluirán ensayos controlados aleatorios (ECA) y cuasialeatorios de pacientes con diagnóstico de HF. Las medidas de resultado los niveles de LDL, HDL pos tratamiento y eventos cardiovasculares. Las búsquedas electrónicas se realizarán en PUBMED, The Coch-rane Central Register of Controlled Trials (CENTRAL), EMBASE y Scientific electronic library (Scielo). En la evaluación del riesgo de sesgo se utilizará la herramienta de Cochrane. Las medidas del efecto del tratamiento serán las diferencias de medias (DM) y los intervalos de confianza (IC) del 95%. La evaluación de heterogeneidad se realizará mediante la inspec-ción visual del diagrama de embudo. La evaluación de la calidad de la evidencia se reali-zará usando la evaluación GRADE.

Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disor-der that produces hypercholesterolemia and premature development of cardiovascular diseas-es. Statins are the drug of choice in these patients; however, a high percentage of patients cannot achieve their therapeutic goals with the maximum recommended doses, so Lo-mitapide may prove to be useful as a new treatment alternative to traditional statins. Objective: The objective of this systematic review is to determine if Lomitapide is better than statins at reducing cardiovascular events in patients with a diagnosis of FH. Methods: Randomized controlled trials (RCTs) and quasi-randomized trials of patients di-agnosed with FH will be included. Primary outcome measures included several parameters: 1. Post-treatment low- and high-density lipoprotein (LDL and HDL, respectively) levels and 2. Presence of cardiovascular events. Electronic searches will be conducted in PUBMED, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the scientific elec-tronic library (Scielo). The assessment of the risk of bias will be used by the Cochrane tool. The measures of the treatment effect will be considered the mean differences (MD) and the 95% confidence intervals (CI). The evaluation of heterogeneity will be done by visual inspec-tion of the funnel diagram. The evaluation of the quality of the evidence will be done using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ap-proach.
Descritores: Doenças Cardiovasculares
Revisão Sistemática
Hidroximetilglutaril-CoA Redutases
Lipoproteínas LDL
-Protocolos
Hipercolesterolemia
LDL-Colesterol
Anticolesterolemiantes
Responsável: EC150


  8 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Texto completo
Id: biblio-1222382
Autor: Torres Valdez, Maritza; Muñoz Avila, Lorena Alexandra; Ortega Espinoza, Carlos Enrique; Mora Bravo, Franklin Geovany; Barzallo Zeas, Diego Fernando.
Título: Reducción de eventos cardiovasculares de Lomitapida versus Estatinas en pacientes con diagnóstico de hipercolesterolemia fa-miliar. Protocolo de revisión sistemática / Reduction of cardiovascular events of Lomitapida versus Statins in patients with a diagnosis of familial hypercholesterolemia: A systematic review protocol
Fonte: Rev. ecuat. pediatr;22(1):1-10, Abril 30, 2021.
Idioma: en.
Resumo: Introducción: La hipercolesterolemia familiar (HF) un trastorno genético autosómico domi-nante que produce un desarrollo prematuro de enfermedades cardiovasculares. Las estati-nas han sido el medicamento de elección en estos pacientes, sin embargo, un buen por-centaje de pacientes no pueden alcanzar sus objetivos terapéuticas con las dosis máximas por lo que la Lomitapida se podría establecer como una nueva alternativa de tratamiento. Objetivo: El objetivo de esta revisión sistemática es determinar si la Lomitapida reduce los eventos cardiovasculares en pacientes con diagnóstico de Hipercolesterolemia familiar comparado con estatinas. Métodos: Se incluirán ensayos controlados aleatorios (ECA) y cuasialeatorios de pacientes con diagnóstico de HF. Las medidas de resultado los niveles de LDL, HDL pos tratamiento y eventos cardiovasculares. Las búsquedas electrónicas se realizarán en PUBMED, The Coch-rane Central Register of Controlled Trials (CENTRAL), EMBASE y Scientific electronic library (Scielo). En la evaluación del riesgo de sesgo se utilizará la herramienta de Cochrane. Las medidas del efecto del tratamiento serán las diferencias de medias (DM) y los intervalos de confianza (IC) del 95%. La evaluación de heterogeneidad se realizará mediante la inspec-ción visual del diagrama de embudo. La evaluación de la calidad de la evidencia se reali-zará usando la evaluación GRADE.

Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disor-der that produces hypercholesterolemia and premature development of cardiovascular diseas-es. Statins are the drug of choice in these patients; however, a high percentage of patients cannot achieve their therapeutic goals with the maximum recommended doses, so Lo-mitapide may prove to be useful as a new treatment alternative to traditional statins. Objective: The objective of this systematic review is to determine if Lomitapide is better than statins at reducing cardiovascular events in patients with a diagnosis of FH. Methods: Randomized controlled trials (RCTs) and quasi-randomized trials of patients di-agnosed with FH will be included. Primary outcome measures included several parameters: 1. Post-treatment low- and high-density lipoprotein (LDL and HDL, respectively) levels and 2. Presence of cardiovascular events. Electronic searches will be conducted in PUBMED, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the scientific elec-tronic library (Scielo). The assessment of the risk of bias will be used by the Cochrane tool. The measures of the treatment effect will be considered the mean differences (MD) and the 95% confidence intervals (CI). The evaluation of heterogeneity will be done by visual inspec-tion of the funnel diagram. The evaluation of the quality of the evidence will be done using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ap-proach.
Descritores: Doenças Cardiovasculares
Revisão Sistemática
Hidroximetilglutaril-CoA Redutases
Lipoproteínas LDL
-Protocolos
Hipercolesterolemia
LDL-Colesterol
Anticolesterolemiantes
Responsável: EC150


  9 / 252 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Texto completo
Id: biblio-1222381
Autor: Torres Valdez, Maritza; Muñoz Avila, Lorena Alexandra; Ortega Espinoza, Carlos Enrique; Mora Bravo, Franklin Geovany; Barzallo Zeas, Diego Fernando.
Título: Reducción de eventos cardiovasculares de Lomitapida versus Estatinas en pacientes con diagnóstico de hipercolesterolemia fa-miliar. Protocolo de revisión sistemática / Reduction of cardiovascular events of Lomitapida versus Statins in patients with a diagnosis of familial hypercholesterolemia: A systematic review protocol
Fonte: Rev. ecuat. pediatr;22(1):1-10, Abril 30, 2021.
Idioma: en.
Resumo: Introducción: La hipercolesterolemia familiar (HF) un trastorno genético autosómico domi-nante que produce un desarrollo prematuro de enfermedades cardiovasculares. Las estati-nas han sido el medicamento de elección en estos pacientes, sin embargo, un buen por-centaje de pacientes no pueden alcanzar sus objetivos terapéuticas con las dosis máximas por lo que la Lomitapida se podría establecer como una nueva alternativa de tratamiento. Objetivo: El objetivo de esta revisión sistemática es determinar si la Lomitapida reduce los eventos cardiovasculares en pacientes con diagnóstico de Hipercolesterolemia familiar comparado con estatinas. Métodos: Se incluirán ensayos controlados aleatorios (ECA) y cuasialeatorios de pacientes con diagnóstico de HF. Las medidas de resultado los niveles de LDL, HDL pos tratamiento y eventos cardiovasculares. Las búsquedas electrónicas se realizarán en PUBMED, The Coch-rane Central Register of Controlled Trials (CENTRAL), EMBASE y Scientific electronic library (Scielo). En la evaluación del riesgo de sesgo se utilizará la herramienta de Cochrane. Las medidas del efecto del tratamiento serán las diferencias de medias (DM) y los intervalos de confianza (IC) del 95%. La evaluación de heterogeneidad se realizará mediante la inspec-ción visual del diagrama de embudo. La evaluación de la calidad de la evidencia se reali-zará usando la evaluación GRADE.

Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disor-der that produces hypercholesterolemia and premature development of cardiovascular diseas-es. Statins are the drug of choice in these patients; however, a high percentage of patients cannot achieve their therapeutic goals with the maximum recommended doses, so Lo-mitapide may prove to be useful as a new treatment alternative to traditional statins. Objective: The objective of this systematic review is to determine if Lomitapide is better than statins at reducing cardiovascular events in patients with a diagnosis of FH. Methods: Randomized controlled trials (RCTs) and quasi-randomized trials of patients di-agnosed with FH will be included. Primary outcome measures included several parameters: 1. Post-treatment low- and high-density lipoprotein (LDL and HDL, respectively) levels and 2. Presence of cardiovascular events. Electronic searches will be conducted in PUBMED, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the scientific elec-tronic library (Scielo). The assessment of the risk of bias will be used by the Cochrane tool. The measures of the treatment effect will be considered the mean differences (MD) and the 95% confidence intervals (CI). The evaluation of heterogeneity will be done by visual inspec-tion of the funnel diagram. The evaluation of the quality of the evidence will be done using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ap-proach.
Descritores: Doenças Cardiovasculares
Revisão Sistemática
Hidroximetilglutaril-CoA Redutases
Lipoproteínas LDL
-Protocolos
Hipercolesterolemia
LDL-Colesterol
Anticolesterolemiantes
Responsável: EC150


  10 / 252 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1132247
Autor: Ahmadvand, Hassan; Nouryazdan, Negar; Nasri, Maryam; Adibhesami, Glavizh; Babaeenezhad, Esmaeel.
Título: Renoprotective Effects of Gallic Acid Against Gentamicin Nephrotoxicity Through Amelioration of Oxidative Stress in Rats
Fonte: Braz. arch. biol. technol;63:e20200131, 2020. tab, graf.
Idioma: en.
Resumo: Abstract Gallic acid (GA), as a strong antioxidant, was selected in this study to investigate its possible nephroprotective effects against gentamicin (GM)-induced nephrotoxicity. Twenty-four rats were separated into three groups (n=8): group 1 (control group) received saline (0.5 mL/day), group 2 (GM group) received GM (100 mg/kg/day), and group 3 (treated group) received GM (100 mg/kg/day) and GA (100mg/kg/day). All treatments were performed intraperitoneally for 12 days. After 12 days, the rats were euthanized, and kidneys were removed immediately. For serum preparation, blood samples were collected before killing. Kidney paraffin sections were prepared from one of the kidneys and stained by the periodic acid-Schiff process. GA significantly decreased GM-induced renal histopathological injuries, including tubular necrosis, tubular cast, and leucocyte infiltration compared with the GM group. Additionally, GA significantly improved proteinuria, serum levels of urea and creatinine, and serum activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) compared with nephrotoxic animals. Furthermore, GA caused a significant improvement in the levels of cholesterol (Chol), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and cardiac risk ratios 1 and 2 in comparison with nephrotoxic animals. GA administration was observed to significantly improve the levels of lipid peroxidation, nitric oxide (NO), and glutathione (GSH) compared with the GM group. Finally, the activities and gene expression levels of catalase (CAT) and glutathione peroxidase (GPX) significantly increased following GA administration compared with the GM group. Our results indicated that GA has potential protective effects against GM nephrotoxicity by reducing oxidative stress in rats.
Descritores: Gentamicinas/efeitos adversos
Estresse Oxidativo/efeitos dos fármacos
Ácido Gálico/uso terapêutico
Nefropatias/tratamento farmacológico
Antibacterianos/efeitos adversos
Antioxidantes/uso terapêutico
-Biomarcadores
Colesterol
Ratos Wistar
Modelos Animais de Doenças
Ácido Gálico/química
Nefropatias/induzido quimicamente
Nefropatias/patologia
Lipoproteínas HDL
Lipoproteínas LDL
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME



página 1 de 26 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde